



SpeedX adds Somagen Diagnostics to Distribution Network

Partnership with Somagen expands SpeedX product availability in Canada

SYDNEY, AUSTRALIA – (September 27, 2024). SpeedX have announced signing a new distribution partner, further extending market access to SpeedX **ResistancePlus**[®] and **PlexPCR**[®] tests. Somagen Diagnostics will distribute the SpeedX **ResistancePlus**[®] MG test throughout Canada.

"We continue to see high demand for our innovative tests and technology around the world," says Warwick Need, SpeedX Director of Sales, "and we are thrilled to partner with Somagen, a likeminded company dedicated to developing a better health care journey for all Canadians".

Antimicrobial resistance (AMR) is one of the top global public health threats. It is estimated that bacterial AMR was directly responsible for 1.27 million deaths worldwide in 2019¹. The burden of AMR to Canadians is equally concerning, with 2,900 deaths in the same year².

"The fight against antibiotic resistance has become a major public health issue. We're excited to now distribute a key product in Canada to aid AMR identification in Mycoplasma genitalium," — Kayla Shea, VP of Commercial, Somagen.

Guidelines for management of infectious diseases are moving away from empiric treatment pathways towards more directed use of antibiotics. Clinicians that follow Resistance Guided Therapy practices have seen a positive impact on patient cure rates³ while reducing overall healthcare costs.

"Often infectious disease testing guidelines and reimbursements now call to consider AMR, highlighting the importance of managing these infections correctly upfront," Need explains, "and that starts with a diagnostic test that detects organism and AMR status simultaneously."

"Currently requiring genetic sequencing to confirm resistance profiles, Canadian labs will now have access to the **ResistancePlus**[®] MG PCR test, which will ultimately improve the patient experience." – remarked Kayla Shea "A PCR approach will vastly reduce the time for clinicians to obtain resistance results, enabling faster provision of correct infection treatment for patients."

ResistancePlus[®] MG is the first SpeedX assay available in Canada.

*Not available in the U.S.

About SpeedX Pty Ltd

Founded in 2009, SpeedX is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeedX specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeedX has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers.

SpeedX **ResistancePlus**[®] tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.

For more information about SpeedX please see: <http://plexpcr.com>

About Somagen

Founded in 1988 in Edmonton, Alberta, Somagen has remained committed to providing patient-focused clinical diagnostic solutions for Canadians. Over 30 years later, Somagen continues to enhance patient care by empowering healthcare professionals with modern technology for early diagnosis, disease monitoring, and treatment. Today, Somagen specializes in a comprehensive range of in-vitro diagnostic medical devices, including Cellular Pathology, Cancer Monitoring, Assisted Reproductive Technology, Chemistry, Infectious Disease, Hematology, and Immunology. As a leader in medical device distribution in Canada, Somagen represents innovative diagnostic product suppliers from around the world.

For more information about Somagen please contact: <https://www.somagen.com>

Michelle Howie
Associate Director | Global Strategic Marketing
michelleh@speedx.com.au
+61 499 743 199

References:

1. **Antimicrobial resistance — World Health Organization**
[https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance#:~:text=It%20is%20estimated%20that%20bacterial,4.95%20million%20deaths%20\(1\)](https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance#:~:text=It%20is%20estimated%20that%20bacterial,4.95%20million%20deaths%20(1))
2. University of Washington www.healthdata.org/sites/default/files/2023-09/Canada.pdf
3. Read TRH *et. al.* CID 2019; 68(4):554-560